The cyclin-dependent kinase inhibitor p21 protects the lung from oxidative stress

被引:97
|
作者
O'Reilly, MA
Staversky, RJ
Watkins, RH
Reed, CK
Jensen, KLD
Finkelstein, JN
Keng, PC
机构
[1] Univ Rochester, Dept Pediat Neonatol, Rochester, NY 14627 USA
[2] Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14627 USA
[3] Univ Rochester, Sch Med & Dent, Dept Radiat Oncol, Rochester, NY 14627 USA
关键词
D O I
10.1165/ajrcmb.24.6.4355
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The lung is a major target tissue for oxidative stress, including hyperoxia used to relieve tissue hypoxia. Unfortunately, severe hyperoxia damages DNA, inhibits proliferation, and kills cells, resulting in morbidity and mortality. Although hyperoxia induces the tumor suppressor p53 and its downstream target, the cyclin-dependent kinase inhibitor p21(Cip1/WAF1/Sdi1) (p21), their role in pulmonary injury remains unknown. Using p53- and p21-deficient mice we demonstrate that hyperoxia induces p21 in the absence of p53, suggesting that previous conclusions that p53 does not modify hyperoxic lung injury cannot be extrapolated to p21. In fact, mean survival of p21-deficient mice decreased by 40% and was associated with terminal deoxyribonucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling staining of alveolar debris, indicative of DNA fragmentation and cell death. Ultrastructural analyses revealed that alveolar endothelial and type I epithelial cells died rapidly by necrosis. Although hyperoxia decreased DNA replication in p21-wild-type lungs, it had no effect on replication in p21-deficient lungs. Our findings suggest that p21 protects the lung from oxidative stress, in part, by inhibiting DNA replication and thereby allowing additional time to repair damaged DNA. Our findings have implications for patients suffering from the toxic effects of supplemental oxygen therapies.
引用
收藏
页码:703 / 710
页数:8
相关论文
共 50 条
  • [1] Purification and crystallization of cyclin-dependent kinase inhibitor p21
    Mayrose, DR
    Nichols, MA
    Yue, XO
    Ke, HM
    PROTEIN SCIENCE, 1996, 5 (09) : 1928 - 1930
  • [2] Cyclin-dependent kinase inhibitor p21 in endometrial carcinoma
    Backe, J
    Caffier, H
    Dietl, J
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 177 (01) : 243 - 243
  • [3] The role of the cyclin-dependent kinase inhibitor p21 in apoptosis
    Gartel, AL
    Tyner, AL
    MOLECULAR CANCER THERAPEUTICS, 2002, 1 (08) : 639 - 649
  • [4] Regulation of the cyclin-dependent kinase inhibitor p21 by an inhibitor of the mevalonate pathway
    Haque, RM
    Lee, SJ
    Nguyen, PM
    Choi, YH
    Pernia, F
    Jang, JS
    Wang, XF
    Kim, SJ
    Trepel, JB
    MOLECULAR BIOLOGY OF THE CELL, 1997, 8 : 801 - 801
  • [5] The cyclin-dependent kinase inhibitor p21 as a target for differentiation therapy
    Manfredi, JJ
    Tang, HY
    Waxman, S
    MOLECULAR AND CELLULAR DIFFERENTIATION, 1996, 4 (01): : 33 - 45
  • [6] Expression of cyclin-dependent kinase inhibitor p21 in human liver
    Crary, GS
    Albrecht, JH
    HEPATOLOGY, 1998, 28 (03) : 738 - 743
  • [7] The p21 cyclin-dependent kinase protects esophageal carcinoma cells from radiation.
    Rigberg, DA
    Kim, FS
    Blinman, TA
    So, J
    McFadden, DW
    GASTROENTEROLOGY, 1998, 114 (04) : A1420 - A1420
  • [8] THE P21 CYCLIN-DEPENDENT KINASE INHIBITOR SUPPRESSES TUMORIGENICITY IN-VIVO
    YANG, ZY
    PERKINS, ND
    OHNO, T
    NABEL, EG
    NABEL, GJ
    NATURE MEDICINE, 1995, 1 (10) : 1052 - 1056
  • [9] Polymorphisms of p21 cyclin-dependent kinase inhibitor and malignant skin tumors
    Konishi, R
    Sakatani, S
    Kiyokane, K
    Suzuki, K
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2000, 24 (03) : 177 - 183
  • [10] A MUTANT P21 CYCLIN-DEPENDENT KINASE INHIBITOR ISOLATED FROM A BURKITTS-LYMPHOMA
    BHATIA, K
    FAN, SJ
    SPANGLER, G
    WEINTRAUB, M
    OCONNOR, PM
    JUDDE, JG
    MAGRATH, I
    CANCER RESEARCH, 1995, 55 (07) : 1431 - 1435